MT Newswires
RBC Lifts Price Target on Ascendis Pharma to $275 From $250, Keeps Outperform, Speculative Risk
📈
AI Sentiment
Highly Positive
8/10
Ascendis Pharma A/S News
Latest updates and market news for ASND
5 news
Feb 25 - Mar 3, 2026
Page 1
GlobeNewswire
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
âž–
AI Sentiment
Neutral
5/10
GlobeNewswire
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Assessing Ascendis Pharma (ASND) Valuation After Strong 1 Year Return And Growing Growth Expectations
📈
AI Sentiment
Highly Positive
8/10
Share this news page